跳至主要内容
临床试验/JPRN-UMIN000009016
JPRN-UMIN000009016已完成未知

Study of second-generation 5-HT3-receptor antagonist; palonosetron for prevention of nausea and emesis in patients receiving chemotherapy including cisplatin for gastric cancer. - Effect of palonosetron in patient receiving chemotherapy including cisplatin for gastric cancer.

Digestive Disease Support Organization (DDSO)0 个研究点目标入组 75 人开始时间: 2012年10月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
75

研究概览

简要总结

Complete response rate: 91.6% Complete protectionrate: 66.7%

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) patients with serious hepatic insufficiency or renal failure. 2) patients with emesis within 24 hours before first administrating of cisplatin. 3) patients who were administered antiemetic drugs within 48 hours before first administrating of cisplatin. 4) patients with emetic factor except for chemotherapy 5) patient who was intended radiation therapy 6) patients judged inappropriate for this study by physicians. 7) patients who received Pimozide.

研究者

发起方
Digestive Disease Support Organization (DDSO)

相似试验